SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher FY2026 revenue outlook, supported by stronger demand for Amtagvi and Proleukin, drove a sharp rally and renewed analyst attention. Traders were largely bullish and discussed possible short covering, while others cautioned about the rapid run-up and potential dilution; upcoming lung-cancer data also featured as a further catalyst to watch.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New HOPE-3 extension data presented at the World Muscle Society showed slower upper-limb decline after patients switched from placebo to deramiocel, driving renewed attention to Capricors Duchenne muscular dystrophy treatment. Traders largely view the findings as supportive of approval, while debate continues over how the FDA will weigh the data amid prior statistical and regulatory disputes.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCNs sharp move higher has fueled breakout and altcoin-season chatter, with some traders attributing it to rumored Robinhood or BlackRock interest; those links remain unconfirmed. Bulls also point to Zebecs payroll and payments partnerships, while skeptics question whether adoption and trading activity are strong enough to sustain the move.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Positive Phase 3 results for Hetlioz in delayed sleep-wake phase disorder are drawing attention, with traders focused on the potential label expansion and new commercial opportunity. The community is broadly encouraged by the trial meeting its primary endpoint, while some note the small study and that FDA discussions and an application are still ahead.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is mainly discussed as a diversified, low-cost core holding for long-term investing, with many traders favoring buy-and-hold and regular contributions. That optimism is tempered by bearish concerns about inflation, rates, geopolitical risks and concentrated AI-related exposure weighing on the broader market.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns upcoming fiscal Q4 earnings report is the dominant focus, with traders watching guidance for signs that AI-driven DRAM and HBM demand, tight supply, and pricing strength will persist. Bullish expectations for a strong report compete with concerns that high expectations are priced in and the memory cycle may not last; the Netlist patent dispute is a secondary risk.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

DIA is drawing attention amid broad-market weakness as rising Treasury yields and oil-driven inflation concerns fuel expectations of further Fed tightening, with uncertainty around the Iran conflict adding to the macro debate. Bearish traders warn of a deeper correction, while others view the pullback as a buying opportunity and point to market resilience.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

A rebound in PENGU has renewed momentum-focused discussion, with bullish traders anticipating a breakout while others warn that rallies have repeatedly faded. A claim that Luca Netz wants to take Pudgy Penguins public and link token and NFT holders is circulating, but it is not broadly corroborated in the discussion.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPM is drawing attention amid a sharp pullback alongside other large-bank stocks, with traders pointing to rising Treasury yields, a flattening yield curve and worries about credit and the economic outlook. The discussion is split between recession and further-downside concerns and dip-buying or bullish options positioning ahead of earnings.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs rebound and push toward resistance are drawing bullish calls for a technical breakout, with traders citing its capped supply and anticipated crypto-market-structure legislation as potential tailwinds. Others remain skeptical, arguing the token has lagged peers and questioning whether the rally can hold.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IRIDEX (IRIX) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%

IRIX's Q2 loss per share widens year over year and revenues decline as Middle East disruptions and reduced sell-through in China weigh on retina sales, offsetting continued growth in the Cyclo G6 product family.


Full Transcript: Iridex Q2 2026 Earnings Call

Iridex (NASDAQ:IRIX) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call.
Benzinga APIs provide real-time access to earnings call transcripts and financial data.read more...

IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth

IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.


Iridex (IRIX) Q1 2026 Earnings Transcript

Iridex Q1 2026 Earnings Call: Complete Transcript

The Zacks Analyst Blog  Microsoft, AbbVie, BHP,  CBL & Associates Properties and IRIDEX 

Microsoft, AbbVie and BHP anchor today???s top analyst reports, highlighting AI growth, drug pipeline strength and rising commodity output shaping outlooks.

Top Analyst Reports for Microsoft, AbbVie & BHP

Microsoft rides AI and Azure growth, but slowing cloud guidance, capacity limits, and rising competition cast a shadow on its momentum.

Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth

IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.

IRIDEX (IRIX) Q4 2025 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. Its products include lasers, laser delivery and glaucoma devices, retinal surgical instruments, veterinary, and ENT. The company was founded by Eduardo Arias, Theodore A. Boutacoff, David M. Buzawa and James L. Donovan in February 1989 and is headquartered in Mountain View, CA.

IRIDEX Corp.

Neutral Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.04	--	--	N/A
Q2 '26	-$0.01	-$0.07	-600.00%	MISSED
Q1 '26	-$0.07	-$0.03	57.14%	BEAT
Q4 '25	-$0.02	-$0.01	50.00%	BEAT
Q3 '25	--	-$0.09	--	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

IRIX Earnings

Upcoming Earnings: Q3 '26

Historical Earnings